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Association of CD14 rs2569190 
polymorphism with mortality 
in shock septic patients who 
underwent major cardiac or 
abdominal surgery: A retrospective 
study
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Alejandra Fadrique2, Eduardo Tamayo2 & Salvador Resino  1
The aim of this study was to investigate the relationship between the CD14 rs2569190 polymorphism 
and death related to septic shock in white European patients who underwent major cardiac or 
abdominal surgery. We carried out a retrospective study in 205 septic shock patients. The septic 
shock diagnosis was established by international consensus definitions. The outcome variable was 
the death within 28, 60 and 90 days after septic shock diagnosis. The CD14 rs2569190 polymorphism 
was analyzed by Agena Bioscience’s MassARRAY platform. For the genetic association analysis with 
survival was selected a recessive inheritance model (GG vs. AA/AG). One hundred thirteen out of 205 
patients (55.1%) died with a survival median of 39 days (95%CI = 30.6; 47.4). Patients with rs2569190 
GG genotype had shorter survival probability than rs2569190 AA/AG genotype at 60 days (62.3% vs 
50%; p = 0.035), and 90 days (62.3% vs 52.6%; p = 0.046). The rs2569190 GG genotype was associated 
with increased risk of septic shock-related death in the first 60 days (adjusted hazard ratio (aHR) = 1.67; 
p = 0.016) and 90 days (aHR = 1.64; p = 0.020) compared to rs2569190 AA/AG genotype. In conclusion, 
the presence of CD14 rs2569190 GG genotype was associated with death in shock septic patients 
who underwent major surgery. Further studies with bigger sample size are required to verify this 
relationship.
Sepsis is a major cause of death from infection, although mortality from sepsis has decreased due to improved 
supportive care and evidence-based guidelines for diagnosis and timely intervention1,2. Besides, septic shock 
kills a large number of patients in hospitals, mainly in intensive care unit (ICU)1–3. In general terms, sepsis is a 
life-threatening organ dysfunction caused by altered host response to infection; and septic shock is a subset of 
sepsis with circulatory and cellular/metabolic abnormalities, which has been related to higher risk of dying4.
In many cases, the stabilization of the clinical condition in septic patients is reached by the use of anti-infective 
treatments together to aggressive organ failure supports1. Nevertheless, these patients are susceptible to 
ICU-related complications, which have a notable repercussion on their early and late prognosis5,6. Thus, multiple 
organ failure caused by the primary infection could mainly explain early deaths and ICU-related complications 
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such as nosocomial infections and mesenteric ischemia could lead to late deaths5. The dysfunction at the molec-
ular level is reflected significantly by the outcome of these patients. In sepsis, the vascular endothelium is consid-
erably affected, appearing changes in the mitochondrial functionality because of the repeated hypoxia episodes. 
This mitochondrial damage may induce a series of cellular and pathophysiological dysfunctions, increasing the 
chances of multiple organ dysfunction syndrome (MODS) and death7.
Lipopolysaccharide (LPS) or endotoxin plays a major role in initiating the typical septic inflammatory cas-
cade with overproduction of proinflammatory cytokines8. LPS is the major component of the outer membrane 
of gram-negative bacteria, but LPS may also trigger inflammation in gram-positive and fungal sepsis due to the 
release of excessive amounts of gut-derived LPS during intestinal hypoperfusion9,10.
CD14, together with toll-like receptor 4 (TLR4) and lymphocyte antigen 96 (LY96, also called MD-2), may 
bind LPS resulting in NF-kB activation and the production of proinflammatory cytokine11. In this regard, there 
are a high number of genes, which are induced by NF-kB, that are implicated in the cellular response against 
infection and promote the synthesis of pro-inflammatory mediators. Additionally, several microRNAs have been 
involved in the NF-kB activity and modulation of the immune response, resulting in a worsening of the sepsis 
with developing of MODS and death. Additionally, several microRNAs have been involved in the NF-kB activity 
and modulation of the immune response, resulting in a worsening of the sepsis with developing of MODS and 
death12.
CD14, a 53–55 kDa glycoprotein, is expressed on the surface (mCD14) of myeloid cells (monocytes, mac-
rophages, and neutrophils) and non-myeloid cells (endothelial and epithelial cells)11. CD14 may also be found in 
a soluble form (sCD14), which apparently derives from the secretion of CD14 or from proteolysis of mCD1411. 
Both mCD14 and sCD14 are critical for LPS-dependent signal transduction. Besides, CD14 may also partici-
pate in immune cell activation by gram-positive cell-wall components13–15. The role of CD14 and the inflamma-
tory response are essential to eradicate primary infections and prevent the acquisition of secondary infections in 
patients with sepsis16. However, CD14 also has a pivotal role in initiating and perpetuating the pro-inflammatory 
response during the course of sepsis17.
A single nucleotide polymorphism (SNP) detected at position −159 in the promoter region of the CD14 
gene (rs2569190) has been related to Sp protein. The presence of a T at −159 decreases the homology between 
the CD14 promoter GC box and the Sp consensus sequence.18, leading to subsequent increases in CD14 produc-
tion18,19. Thus, the rs2569190 SNP increases the level of pro-inflammatory response following LPS stimulation 
because it could modulate the transcriptional activity of CD1419,20. The CD14 rs2569190 polymorphism has been 
related to susceptibility to sepsis, as well as the outcome of sepsis17, but there are controversial results due to the 
small sample size and the heterogeneity of the patients included in the previous studies.
In this study, we analyzed the relationship between the CD14 rs2569190 polymorphism and death in European 
septic shock patients who underwent major surgery.
Results
Population characteristics. Epidemiological and clinical characteristics of septic shock patients at the 
moment of septic shock diagnosis and stratified by CD14 rs2569190 genotype are shown in Table 1. In brief, 
63.9% were male, the median age was 73 years and 54.6% and 44.9% of patients had hypertension and heart dis-
ease, respectively. Regarding the surgery, 40% of patients were underwent cardiac surgery and 63.4% of surgery 
were urgent. The most predominant pathogens were gram-negatives (52.7%). Regarding site of infection, 46.8% 
and 47.3% of patients had peritonitis or pneumonia, respectively. When the population was divided taken into 
consideration CD14 rs2569190 genotype under a recessive genetic model, we did not find any significant differ-
ences between groups.
Frequency of the CD14 polymorphism. The frequencies of CD14 rs2569190 polymorphism in patients 
and control groups (patients with systemic inflammatory response syndrome (SIRS) and healthy subjects 
from the Iberian populations in Spain (IBS)21) are shown in Table 2. The CD14 rs2569190 polymorphism was 
in Hardy–Weinberg equilibrium (HWE) (p > 0.05) and showed missing values <5%. Significant differences in 
allelic and genotypic frequencies were not found among groups.
CD14 polymorphism and septic shock-related death. For the genetic association study, a recessive 
inheritance model (GG vs. AA/AG) was selected, due to it was the model that best fit to our data. The survival 
probabilities at different time points (28, 60, and 90 days) after septic shock diagnosis are shown in Table 3. One 
hundred thirteen out of 205 patients (55.1%) died with a survival median of 39 days (95%CI = 30.6; 47.4). Patients 
with CD14 rs2569190 GG genotype had higher death probability than CD14 rs2569190 AA/AG genotype at 60 
days (p = 0.035), and 90 days (p = 0.046) (Fig. 1). The death risks at 28, 60, and 90 days obtained by Cox regres-
sion for the CD14 rs2569190 polymorphism are shown in Table 4. The CD14 rs2569190 GG genotype was related 
to bigger adjusted risk of death related to septic shock at day 60 (adjusted hazard ratio (aHR) = 1.67; p = 0.016) 
and day 90 (aHR = 1.64; p = 0.020) than CD14 rs2569190 AA/AG genotype.
Finally, the risk of death regarding CD14 rs2569190 polymorphism was separately assessed for patients under-
went cardiac and abdominal surgery. In patients underwent cardiac surgery, the CD14 rs2569190 GG carriers had 
higher risk of death related to septic shock during the first 60 days [aHR = 2.26 (95%CI = 1.08; 4.82); p = 0.029] 
and 90 days [aHR = 2.07 (95%CI = 1.01; 4.29); p = 0.049] than CD14 rs2569190 AA/AG carrier; whereas CD14 
rs2569190 GG carriers who underwent abdominal surgery did not have any significant association with mortality 
related to septic shock during the first 28, 60 and 90 days after diagnosis.
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No. patients 205 152 53 —
Gender (male) 131 (63.9%) 100 (65.8%) 31 (58.5%) 0.341
Age (years) 73. (63; 79.5) 72 (63; 79.7) 77 (67.5; 79.5) 0.137
Prior or pre-existing conditions
 Smoker 36 (17.6%) 27 (17.8%) 9 (17.0%) 0.897
 Alcoholism 15 (7.3%) 9 (5.9%) 6 (11.3%) 0.194
 Obesity 30 (14.6%) 18 (11.8%) 12 (22.6%) 0.055
 Diabetes 26 (12.7%) 17 (11.2%) 9 (17.0%) 0.275
 Heart disease 92 (44.9%) 71 (46.7%) 21 (39.6%) 0.372
 Chronic obstructive pulmonary disease 36 (17.6%) 24 (15.8%) 12 (22.6%) 0.259
 Hypertension 112 (54.6%) 81 (53.3%) 31 (58.5%) 0.513
 Chronic kidney disease 30 (14.6%) 23 (15.1%) 7 (13.2%) 0.733
 Cancer 48 (23.4%) 31 (20.4%) 17 (32.1%) 0.084
 Liver disease 9 (4.4%) 6 (3.9%) 3 (5.7%) 0.600
Surgery
 Cardiac (versus abdominal) 82 (40.0%) 62 (40.8%) 20 (37.7%) 0.696
 Emergency (versus scheduled) 130 (63.4%) 97 (63.8%) 33 (62.3%) 0.840
Severity indexes
 SOFA score 9 (7; 10.5) 9 (7; 10) 9 (7; 11) 0.510
 APACHE II score 16 (14; 19) 16 (13; 19) 17 (14; 21.5) 0.060
Infection
 Gram-positive 102 (49.8%) 81 (53.3%) 21 (39.6%) 0.087
 Gram-negative 108 (52.7%) 78 (51.3%) 30 (56.6%) 0.507
 Fungus 41 (20.0%) 34 (22.4%) 7 (13.2%) 0.151
 Catheter bacteraemia 70 (34.1%) 55 (36.2%) 15 (28.3%) 0.297
 Surgical site infection 49 (23.9%) 35 (23.0%) 14 (26.4%) 0.618
 Urinary tract infection 24 (11.7%) 15 (9.9%) 9 (17.0%) 0.165
 Endocarditis 10 (4.9%) 8 (5.3%) 2 (3.8%) 0.665
 Peritonitis 96 (46.8%) 72 (47.4%) 24 (45.3%) 0.793
 Pneumonia 97 (47.3%) 69 (45.4%) 28 (52.8%) 0.351
Table 1. Summary of epidemiological and clinical characteristics of septic shock patients who underwent 
major surgery according to CD14 polymorphism. Values are expressed as absolute count (percentage) and 
median (percentile 25; percentile 75). (*)P-values were calculated by Chi-square test or Fisher’s exact test for 
categorical variables and Mann-Whitney test for continuous variables. Statistically significant differences 
are shown in bold. Note that patients may have had more than one organism cultured. Abbreviations: SOFA, 
sequential organ failure assessment; APACHE, acute physiology and chronic health evaluation; CD14, cluster 
of differentiation 14.
SNP IBS population SIRS patients Septic shock patients p-value(a) p-value(b)
No. 107 259 205
HWE (p-value) 0.149 0.768 0.238
Alleles G 51.4% 51.2% 48.8% 0.939 0.660
A 48.6% 48.8% 51.2% — —
Genotypes AA 29.9% 24.1% 28.5% 0.235 0.765
AG 43.0% 49.4% 45.9% 0.294 0.629
GG 27.1% 26.5% 25.9% 0.988 0.812
Table 2. Frequencies of alleles and genotypes for CD14 rs2569190 polymorphism in septic shock patients 
compared to Iberian populations in Spain from 1000 Genomes Project data (http://www.1000genomes.
org/1000-genomes-browsers) and SIRS patients. P-values were calculated by Chi-squared test: (a) differences 
between IBS population and septic shock patients; (b) differences between SIRS patients and septic shock 
patients. Abbreviations: SIRS, patients with systemic inflammatory response syndrome; IBS, Iberian 
populations in Spain; HWE, Hardy-Weinberg equilibrium; CD14, cluster of differentiation 14.
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Discussion
The genetic variation at genes of innate immunity may have influence on the occurrence of sepsis and death22,23. 
In this study, we found a relationship between CD14 rs2569190 polymorphism and mortality in European sep-
tic shock patients who underwent major surgery. Specifically, patients with CD14 rs2569190 GG genotype had 








28 days 36.1% 32.9% 45.3% 0.095
60 days 53.2% 50.0% 62.3% 0.035
90 days 55.1% 52.6% 62.3% 0.046
Table 3. Survival probabilities at 28, 60, and 90 days (Kaplan-Meier product limit method) for CD14 rs2569190 
polymorphism in septic shock patients who underwent major cardiac or abdominal surgery. Abbreviations: 
CD14, cluster of differentiation 14; p-value, level of significance.
Figure 1. Survival analysis (Kaplan-Meier curve) regarding to CD14 rs2569190 polymorphism in septic shock 
patients who underwent major cardiac or abdominal surgery. P-values were calculated by log-rank test (Kaplan-
Meier curve).
Univariate Multivariate
HR 95%CI p-value aHR 95%CI p-value(*)
The first 28 days
 rs2569190 GG 1.50 0.92; 2.45 0.101 1.55 0.95; 2.53 0.077
 Emergency surgery 1.86 1.00; 3.46 0.049
 APACHE-II score 1.04 1.00; 1.08 0.067
 Peritonitis 2.28 1.35; 3.85 0.002
 Heart disease 1.97 1.20; 3.22 0.007
The first 60 days
 rs2569190 GG 1.54 1.02; 2.33 0.039 1.67 1.10; 2.54 0.016
 Emergency surgery 1.86 1.18; 2.92 0.007
 Peritonitis 1.84 1.19; 2.86 0.006
 Heart disease 1.72 1.13; 2.63 0.012
 Liver disease 1.91 0.82; 4.47 0.133
The first 90 days
 rs2569190 GG 1.50 1.00; 2.26 0.050 1.64 1.08; 2.48 0.020
 Emergency surgery 1.89 1.21; 2.95 0.005
 Peritonitis 1.83 1.18; 2.82 0.007
 Heart disease 1.70 1.12; 2.58 0.012
 Liver disease 1.92 0.82; 4.47 0.132
Table 4. Risk of death regarding CD14 rs2569190 polymorphism in septic shock patients who underwent 
major cardiac or abdominal surgery. (*)P-values were calculated by Cox regression adjusting for the most 
important clinical and epidemiological characteristics (see statistical analysis section). Abbreviations: CD14, 
cluster of differentiation 14; HR, hazard ratio; aHR, adjusted hazard ratio; 95%CI, 95% confidence interval; 
p-value, level of significance.
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increased risk of death related to septic shock, suggesting that CD14 rs2569190 polymorphism may have an 
important function in the pathogenesis of septic shock. To our knowledge, this is the first report describing these 
findings in patients who underwent major surgery, while remaining consistent with observations in critically ill 
patients with medical conditions24,25 or burn injury26,27.
To date, discrepant results have been described for the association between CD14 rs2569190 polymorphism 
and sepsis and death17.
In 2013, a meta-analysis of Zhang et al.17 suggested that the CD14 rs2569190 polymorphism could not be a 
relevant risk factor for sepsis and mortality because only weak associations were found in Asian populations and 
septic shock patients. They found that patients with AA/AG genotypes had a tendency towards higher risk of 
death than patients with GG genotype17. However, our results are not consistent with this meta-analysis, since we 
observed a beneficial effect of the AA/AG genotype on septic shock survival in European people. Note that the 
meta-analysis by Zhang et al. did not provide information about the association of CD14 rs2569190 polymor-
phism with septic-shock survival in European populations. This was probably due to the low number of sepsis 
mortality-related studies included in the meta-analysis, which precluded the stratification by ethnicity17. In addi-
tion, other specific studies have associated CD14 rs2569190 G allele with higher risk of sepsis and death in people 
of European origin, which may support our results18,26–30.
The A to G polymorphism at position-159 in the promoter region of the CD14 gene (rs2569190) could 
cause differential activity in promoter constructs. In this context, rs2569190 G allele seems to be implicated in 
down-regulation of CD14 transcription and lower expression of mCD14 and circulating levels of sCD1419,20. 
With this in mind, previous reports suggest that the biological correlation of the CD14 rs2569190 polymorphism 
with the survival in patients with A-allele could be attributed to the strongest pro-inflammatory response among 
patients, consequence of higher CD14 expression19,20,31–33. This assumption is consistent with the increasingly 
prevailing opinion that the major problem of sepsis patients is the predominant state of immunosuppression 
characterized by a reduced pro-inflammatory status and increased anti-inflammatory response16. In our study, 
assays for determination of mCD14 or sCD14 could support the effect observed for CD14 rs2569190 polymor-
phism, however CD14 values were not available in our study.
Additionally, sCD14 level has been recently described as a novel marker for postoperative mortality in elective 
cardiac surgery patients, showing implication at different times (30-day, 6-month and 2 year-mortality)34. In our 
study, we observed an effect of CD14 rs2569190 polymorphism at 60 and 90-day mortality. As the mortality is a 
cumulative variable, a more limited number of patients suffering death at 28-day mortality compared to 60- and 
90-day mortality was found, which may have decreased the statistical power of our analysis. However, we found a 
trend of association in the multivariate model (p = 0.077), which would be in concordance with previous findings 
described by Mansur et al., who found that CD14 rs2569190 may act as a prognostic variable for the short-term 
outcome due to its association with 30-day mortality in patients with sepsis29.
In this study, we were not able to carry out a study to decipher the mechanisms underlying this association 
because we did not have access to other samples of these patients. However, we carried out an in silico study 
for assessing the regulatory features of this polymorphism taking into account chromatin state of the region 
surrounding variant, regulatory elements overlapped with variant, and variant’s potential target genes. We used 
rVarBase database34,35, which uses experimentally supported regulatory elements from ENCODE and other data 
resources to make relevant annotation. We found that rs2569190 polymorphism, located within the promoter of 
CD14, influence the chromatin states in different cell lines such as neutrophils, monocytes, natural killer cells, T 
cells and B cells from peripheral blood as well as hepatic cells from the liver. Keeping this in mind, we stress the 
importance of further investigations to study the mechanisms that could be influencing the association of CD14 
rs2569190 with septic shock-related death.
We compared frequencies of CD14 rs2569190 alleles and genotypes between septic shock and SIRS patients 
recruited in this study and healthy people obtained from IBS35. No significant differences among groups were 
observed, indicating no bias for the distribution of CD14 rs2569190 polymorphism in our study. In addition, a 
particular strength of this study lies in the fact that there not were baseline differences in clinical and epidemio-
logical variables according to CD14 rs2569190 genotypes (AA/AG vs GG). Despite this, we included the clinical 
and epidemiological variables into the multivariate Cox-regression analysis, and CD14 rs2569190 GG genotype 
remained a significant risk factor for mortality in 60 days and 90 days. In addition to the CD14 rs2569190 poly-
morphism, we observed several factors that were related to death such as emergency surgery, APACHE-II score, 
peritonitis, and heart disease. However, although we evaluated an elevated number of known variables influ-
encing sepsis, other factors not included in this study could have an important role in this issue. Besides, other 
genetic variants could synergistically act with CD14 rs2569190 polymorphism, participating in the occurrence of 
death in septic patients. These factors could be other previously described SNPs within the inflammatory-related 
genes that have been related to death36.
In addition, note that CD14 rs2569190 polymorphism could also influence other sepsis types. In fact, we also 
investigated the association between CD14 rs2569190 polymorphism and severe sepsis by using a small cohort of 
43 patients who developed severe sepsis after cardiac or abdominal surgery (data not shown), finding an associa-
tion between CD14 rs2569190 polymorphism and 90-day mortality (p = 0.033). This underlines the probable role 
of CD14 rs2569190 polymorphism on the other sepsis types, but further analysis with bigger sample size would 
be needed to corroborate such association.
Finally, it should be stressed that this retrospective study has a relatively small sample size, which could 
increase the number of false positives or negatives. Complex human diseases, such as sepsis, are under the control 
of many genes that contribute with modest individual effects. The sample size could be an important issue in 
this regard, since only big effects would be detected in small populations. However, our cohort was homogenous 
because we only included septic shock patients, without including other stages of sepsis. We also carried out a 
follow-up study and survival analysis, which are often much more sensitive to detect statistical associations in 
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cohort studies. Besides, the fact of finding a significant association at different times even when CD14 rs2569190 
polymorphism is studied in combination with other important prognostic factors, reinforces the role of this 
polymorphism on septic shock-related death. However, further studies with bigger sample size would be needed 
to corroborate such association. Moreover, in our study, the association of CD14 rs2569190 polymorphism with 
mortality related to septic shock was only observed in patients underwent major cardiac surgery; whereas patients 
underwent abdominal surgery did not show any significant association. In this setting, note that the reduced sam-
ple size of surgery groups could influence the different pattern observed between cardiac and abdominal surgery. 
Besides, the association should also be investigated in different racial groups. Finally, other CD14 polymorphisms 
could provide interesting information and thus, they should also be evaluated in further studies.
In conclusion, CD14 rs2569190 GG genotype was associated with mortality in patients with septic shock who 
underwent major surgery. The CD14 rs2569190 polymorphism could allow an improved management of death 
risk in septic shock patients. Further studies with bigger sample size are required to verify this relationship.
Materials and Methods
Patients and study design. We performed a retrospective study in 205 patients who developed septic 
shock after major cardiac or abdominal surgery. All patients were white European older than 18 years and were 
attended at the Hospital Clínico Universitario of Valladolid (Spain) between April 2008 and November 2012.
The study was carried out according to the Declaration of Helsinki and patients gave their informed con-
sent for being enrolled in the study. This study was approved by the Ethics Committee of Hospital Clínico 
Universitario (Valladolid) and Instituto de Salud Carlos III (Majadahonda).
Control groups. We included a control group of 257 patients who underwent major cardiac or abdominal 
surgery and only developed SIRS37. Control group had similar age and gender compared to patients group. They 
were attended at the same hospital between 2008 and 2012.
Besides, allelic and genotypic frequencies of CD14 rs2569190 for healthy subjects were collected from the 
1000 Genomes Project website (http://www.1000genomes.org/home) in order to compare these frequencies 
to those obtained from our study. This database covers a wide number of common human genetic variation 
detected by next generation sequencing in multiple populations21. We select the IBS population which involved 
107 individuals.
Control group and IBS population were used to compare the allelic and genotypic frequencies of CD14 
rs2569190 with those obtained from our study.
Clinical data. Major surgery was called to a surgical procedure in which the patient was under general anes-
thesia and respiratory assistance due to the patient was not able to breathe independently. Epidemiological and 
clinical data were collected from medical records: age, gender, type of surgery, prior comorbidities such as diabe-
tes, hypertension, chronic kidney disease, chronic obstructive pulmonary disease, liver disease, cardiomyopathy 
and cancer. In all cardiac surgeries, cardiopulmonary bypass was performed. Severity of sepsis was evaluated by 
using two ICU scoring systems calculated within the first 24 hours after diagnosis: Acute Physiology and Chronic 
health Evaluation (APACHE II score)38 and Sequential Organ Failure Assessment (SOFA score)39.
The septic shock diagnosis was carried out by using the criteria established by the SCCM/ESICM/ACCP/
ATS/SIS International Sepsis Definitions Conference37. According to clinical findings, infection could be either 
documented or presumed. In those cases where the presence of infection was strongly suspected without micro-
biological confirmation, two clinicians with a large experience discussed and reached a consensus diagnosis based 
on clinical and laboratory results.
DNA genotyping. Genomic DNA was extracted from whole blood using High Pure PCR Template 
Preparation kit (Roche Diagnostics GmbH, Mannheim, Germany). CD14 rs2569190 polymorphism was geno-
typed at the Spanish National Genotyping Center (CeGen; http://www.cegen.org/). Genotyping was performed 
by Agena Bioscience’s MassARRAY platform (San Diego, CA, USA) using the iPLEX® Gold assay design system. 
Duplicated samples were included on each plate to check for technical replicates and negative and positive con-
trols were used on each batch to exclude DNA contamination and ensure a technically correct laboratory process.
Outcome variable. The outcome variable was the death, censuring at different time points after septic shock 
diagnosis: 28 days (early mortality), 60 days (middle mortality), and 90 days (late mortality).
Statistical analysis. Nonparametric tests were used for the description of the study population: 
Mann-Whitney U test was conducted for continuous variable and chi-squared/Fisher’s exact test for categori-
cal variables. For the genetic association study, Kaplan-Meier and Cox regression analyses were performed to 
compare the mortality during the first 28, 60 and 90 days according to the presence of CD14 rs2569190 GG 
genotype. Statistical analysis was carried out in accordance with dominant, recessive and additive models. These 
analyses were assessed according to the goodness of fit evaluated by Akaike information criterion (AIC) value and 
Bayesian information criterion (BIC).
Follow-up was censored at different time points: 28, 60 and 90 days. The Kaplan-Meier product-limit method 
at 28, 60, and 90 days and Log rank test were used to estimate and compare survival probabilities. Cox regression 
analyses were used to study the association between CD14 rs2569190 polymorphism and the mortality during the 
first 28, 60, and 90 days after diagnosis of septic shock. Each Cox regression was adjusted by the most important 
clinical and epidemiological co-variables, allowing to avoid the over-fitting of the regression. CD14 rs2569190 
polymorphism was included by forced entry (Enter algorithm) and the most significant co-variables were selected 
by stepwise algorithm (at each step, co-variables are considered for entry or removal: a p-value for entry and exit 
of 0.15 and 0.20, respectively). The co-variables used were age, gender, type of surgery, (cardiac or abdominal), 
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elective surgery (emergency or scheduled), comorbidities (obesity, diabetes, hypertension, heart disease, chronic 
obstructive pulmonary disease (COPD)), liver disease and neoplasia), smoker, and high alcohol intake, antibi-
otic treatment, peritonitis and APACHE-II score. All statistical analyses were carried out by using the IBM SPSS 
Statistics for Windows, Version 21.0 (IBM Corp, Chicago, Armonk, NY, USA). All p-values were two-tailed and 
statistical significance was defined as p < 0.05. Moreover, HWE analyses was performed by Haploview 4.2 soft-
ware, considering equilibrium when p > 0.05.
Data availability. All data generated or analyzed during this study are included in this published article. 
The datasets generated during and/or analyzed during the study are available from the corresponding author on 
reasonable request.
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